D1 Capital Partners, an investment firm, and Eventide Asset Management, an investment adviser, led a $100m Series B funding round in LEXEO Therapeutics, a clinical-stage gene therapy company. Additional investors included CAM Capital, Verition Fund Management, Laurion Capital Management, Gray’s Creek Capital Partners. Existing investors Longitude Capital, Omega Funds, Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Woodline Partners, Invus Capital, and Alexandria Venture Investments also joined the round. “As we embark on our next phase of growth, we are highly encouraged by the support of this diverse range of long-term focused investors participating in our Series B financing,” Nolan Townsend, LEXEO Therapeutics CEO.